Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
Détails
ID Serval
serval:BIB_498102734DE0
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Time to Switch to Second-line Antiretroviral Therapy in Children With Human Immunodeficiency Virus in Europe and Thailand.
Périodique
Clinical infectious diseases
Collaborateur⸱rice⸱s
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) Study Group in EuroCoord
Contributeur⸱rice⸱s
Hainaut M., Van der Kelen E., Delforge M., Warszawski J., Le Chenadec J., Ramos E., Dialla O., Wack T., Laurent C., Ait Si Selmi L., Leymarie I., Ait Benali F., Brossard M., Boufassa L., Floch-Tudal C., Firtion G., Hau I., Chace A., Bolot P., Éphane Blanche S., Èle Granier M., Labrune P., Lachassine E., Dollfus C., Levine M., Fourcade C., Heller B., Runel-Belliard C., Ëlle Tricoire J., Chirouze C., Reliquet V., Brouard J., Kebaili K., Lalande M., Mazingue F., Partisani M.L., Königs C., Schultze-Strasser S., Baumann U., Niehues T., Neubert J., Kobbe R., Feiterna-Sperling C., Königs C., Buchholz B., Notheis G., Spoulou V., Angelo Tovo P., Galli L., Chiappini E., Patrizia O., Larovere D., Ruggeri M., Faldella G., Baldi F., Badolato R., Montagnani C., Venturini E., Lisi C., Di Biagio A., Taramasso L., Giacomet V., Erba P., Esposito S., Lipreri R., Salvini F., Tagliabue C., Cellini M., Bruzzese E., Lo Vecchio A., Rampon O., Donà D., Romano A., Dodi I., Maccabruni A., Consolini R., Bernardi S., Tchidjou Kuekou H., Genovese O., Olmeo P., Cristiano L., Mazza A., Garazzino S., Pellegatta A., Kinderziekenhuis E., Pajkrt D., Scherpbier H.J., Weijsenfeld A.M., van der Plas A., Jurriaans S., Back NKT, Zaaijer H.L., Berkhout B., Cornelissen MTE, Schinkel C.J., CWolthers K., Mc-Sophia E., Fraaij PLA, van Rossum AMC, van der Knaap L.C., Visser E.G., Boucher CAB, Koopmans MPG, van Kampen JJA, Pas S.D., Henriet SSV, van de Flier M., van Aerde K., Strik-Albers R., Rahamat-Langendoen J., Stelma F.F., Schölvinck E.H., de Groot-de Jonge H., Niesters HGM, van Leer-Buter C.C., Knoester M., Bont L.J., Geelen SPM, Wolfs TFW, Nauta N., W Ang C., van Houdt R., Pettersson A.M., Vandenbroucke-Grauls CMJE, Reiss P., Bezemer D.O., I van Sighem A., Smit C., M N Wit F.W., Boender T.S., Zaheri S., Hillebregt M., de Jong A., Bergsma D., Grivell S., Jansen A., Raethke M., Meijering R., de Groot L., van den Akker M., Bakker Y., Claessen E., El Berkaoui A., Koops J., Kruijne E., Lodewijk C., Munjishvili L., Peeck B., Ree C., Regtop R., Ruijs Y., Rutkens T., Schoorl M., Timmerman A., Tuijn E., Veenenberg L., van der Vliet S., Wisse A., Woudstra T., Tuk B., Marczynska M., Oldakowska A., Popielska J., Coupland U., Doroba M., Marques L., Teixeira C., Fernandes A., Ene L., Gingaras C., Radoi R., Okhonskaia L., Voronin E., Miloenko M., Labutina S., Soler-Palacín P., Frick M.A., Pérez-Hoyos S., Mur A., López N., Méndez M., Mayol L., Vallmanya T., Calavia O., García L., Coll M., Pineda V., Rius N., Rovira N., Dueñas J., Fortuny C., Noguera-Julian A., José Mellado M., Escosa L., Hortelano M.G., Sainz T., González-Tomé M.I., Rojo P., Blázquez D., Tomás Ramos J., Prieto L., Guillén S., Navarro M.L., Saavedra J., Santos M., Muñoz M.A., Ruiz B., Mc Phee C.F., de Ory S.J., Alvarez S., Ángel Roa M., Beceiro J., Martínez J., Badillo K., Apilanez M., Pocheville I., Garrote E., Colino E., Sirvent J.G., Garzón M., Román V., Montesdeoca A., Mateo M., Muñoz M.J., Angulo R., Neth O., Falcón L., Terol P., Luis Santos J., Moreno D., Lendínez F., Grande A., José F., Pérez C., Lillo M., Losada B., Herranz M., Bustillo M., Guerrero C., Collado P., Antonio Couceiro J., Pérez A., Isabel Piqueras A., Bretón R., Segarra I., Gavilán C., Jareño E., Montesinos E., Dapena M., Álvarez C., Andrés A.G., Marugán V., Ochoa C., Alfayate S., Menasalvas A.I., de Miguel E., Naver L., Soeria-Atmadja S., Hagås V., Aebi-Popp K., Asner S., Aubert V., Battegay M., Baumann M., Bernasconi E., Böni J., Brazzola P., Bucher H.C., Calmy A., Cavassini M., Ciuffi A., Duppenthaler A., Dollenmaier G., Egger M., Elzi L., Fehr J., Fellay J., Francini K., Furrer H., Fux C.A., Grawe C., Günthard H.F., Haerry D., Hasse B., Hirsch H.H., Hoffmann M., Hösli I., Kahlert C., Kaiser L., Keiser O., Klimkait T., Kovari H., Kouyos R.D., Ledergerber B., Martinetti G., Martinez de Tejada B., Metzner K.J., Müller N., Nicca D., Paioni P., Pantaleo G., Polli C., Posfay-Barbe K., Rauch A., Rudin C., Schmid P., Scherrer A.U., Speck R., Tarr P., Thanh Lecompte M., Trkola A., Vernazza P., Wagner N., Wandeler G., Weber R., Wyler C.A., Yerly S., Techakunakorn P., Hansudewechakul R., Wanchaitanawong V., Theansavettrakul S., Nanta S., Ngampiyaskul C., Phanomcheong S., Hongsiriwon S., Karnchanamayul W., Kwanchaipanich R., Kanjanavanit S., Kamonpakorn N., Nantarukchaikul M., Layangool P., Mekmullica J., Lucksanapisitkul P., Watanayothin S., Lertpienthum N., Warachit B., Hanpinitsak S., Potchalongsin S., Thanasiri P., Krikajornkitti S., Attavinijtrakarn P., Srirojana S., Bunjongpak S., Puangsombat A., Na-Rajsima S., Ananpatharachai P., Akarathum N., Lawtongkum W., Kheunjan P., Suriyaboon T., Saipanya A., Than-In-At K., Jaisieng N., Suaysod R., Chailoet S., Naratee N., Kawilapat S., Kaleeva T., Baryshnikova Y., Soloha S., Bashkatova N., Raus I., Glutshenko O., Ruban Z., Prymak N., Kiseleva G., Bailey H., Lyall H., Butler K., Doerholt K., Foster C., Klein N., Menson E., Riordan A., Shingadia D., Tudor-Williams G., Tookey P., Welch S., Collins I.J., Cook C., Dobson D., Fairbrother K., M Gibb D., Judd A., Harper L., Parrott F., Tostevin A., Van Looy N., Butler K., Walsh A., Scott S., Vaughan Y., Welch S., Laycock N., Bernatoniene J., Finn A., Hutchison L., Sharpe G., Williams A., G H Lyall E., Seery P., Lewis P., Miles K., Subramaniam B., Hutchinson L., Ward P., Sloper K., Gopal G., Doherty C., Hague R., Price V., Bamford A., Bundy H., Clapson M., Flynn J., M Gibb D., Klein N., Novelli V., Shingadia D., Ainsley-Walker P., Tovey P., Gurtin D., P Garside J., Fall A., Porter D., Segal S., Ball C., Hawkins S., Chetcuti P., Dowie M., Bandi S., Eisenhut M., Handforth J., K Roy P., Flood T., Liebeschuetz S., Kavanagh C., Murphy C., Rowson K., Tan T., Daniels J., Lees Y., Kerr E., Thompson F., Le Provost M., Williams A., Cliffe L., Smyth A., Stafford S., Freeman A., Reddy T., Fidler K., Christie S., Gordon A., Rogahn D., Harris S., Hutchinson L., Collinson A., Hutchinson L., Jones L., Offerman B., Van Someren V., Benson C., Riordan A., Riddell A., O'Connor R., Brown N., Ibberson L., Shackley F., N Faust S., Hancock J., Doerholt K., Donaghy S., Prime K., Sharland M., Storey S., Gorman S., G H Lyall E., Monrose C., Seery P., Tudor-Williams G., Walters S., Cross R., Menson E., Broomhall J., Hutchinson L., Scott D., Stroobant J., Bridgwood A., McMaster P., Evans J., Gardiner T., Jones R., Gardiner K.
ISSN
1537-6591 (Electronic)
ISSN-L
1058-4838
Statut éditorial
Publié
Date de publication
01/02/2018
Peer-reviewed
Oui
Volume
66
Numéro
4
Pages
594-603
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Data on durability of first-line antiretroviral therapy (ART) in children with human immunodeficiency virus (HIV) are limited. We assessed time to switch to second-line therapy in 16 European countries and Thailand.
Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks.
Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch.
One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch.
Children aged <18 years initiating combination ART (≥2 nucleoside reverse transcriptase inhibitors [NRTIs] plus nonnucleoside reverse transcriptase inhibitor [NNRTI] or boosted protease inhibitor [PI]) were included. Switch to second-line was defined as (i) change across drug class (PI to NNRTI or vice versa) or within PI class plus change of ≥1 NRTI; (ii) change from single to dual PI; or (iii) addition of a new drug class. Cumulative incidence of switch was calculated with death and loss to follow-up as competing risks.
Of 3668 children included, median age at ART initiation was 6.1 (interquartile range (IQR), 1.7-10.5) years. Initial regimens were 32% PI based, 34% nevirapine (NVP) based, and 33% efavirenz based. Median duration of follow-up was 5.4 (IQR, 2.9-8.3) years. Cumulative incidence of switch at 5 years was 21% (95% confidence interval, 20%-23%), with significant regional variations. Median time to switch was 30 (IQR, 16-58) months; two-thirds of switches were related to treatment failure. In multivariable analysis, older age, severe immunosuppression and higher viral load (VL) at ART start, and NVP-based initial regimens were associated with increased risk of switch.
One in 5 children switched to a second-line regimen by 5 years of ART, with two-thirds failure related. Advanced HIV, older age, and NVP-based regimens were associated with increased risk of switch.
Mots-clé
HIV, antiretroviral therapy, children, second-line, switch
Pubmed
Création de la notice
12/02/2018 11:44
Dernière modification de la notice
29/06/2022 5:37
Données d'usage
